Neuroplast BV is an independent company founded in 2013 and embedded in the Science Society of Brightlands Maastricht, Netherlands. The company is founded and driven by professionals able to translate basic science in concrete strategies, and to commercialize these concepts to the market. Transparency by sharing their experimental developments, results and ideas with the world-wide medical community is considered essential to reach these goals. Neuroplast’s starting point is to develop therapeutic strategies interfering with the various processes leading to neurodegeneration by reducing inflammation and increasing neuroplasticity (neuroprotection, neurorepair), an unmet need in many idiopathic, traumatic and ischemic neurodegenerative disorders.
Optimizing patients’ own stem cells for acute spinal cord lesions, ALS and others.